Sunday 18 October 2026
Export ABVC’s income statement to Excel — free account
ABVC BioPharma, Inc.
ABVC Healthcare Biotechnology
ABVC BioPharma, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $509,600.00, up 234.4% from fiscal 2023. In the quarter to June 2026, revenue grew 66,233.3%, EPS grew 76.9% and free cash flow grew 72.7%, each against the same quarter a year earlier.
0.92
0.01
−1.08%
Follow ABVC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 5 |
+8 more TTM periods Free account |
| (65.32%) | (83.01%) | (112.81%) | (52.27%) | ||
| (39.88%) | (49.85%) | (55.30%) | (32.92%) | ||
ROIC |
(33.45%) | (39.75%) | (37.54%) | (26.04%) | |
Return on Tangible Assets |
(94.14%) | (106.78%) | (86.22%) | (61.03%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.10) | (0.13) | (0.15) | (0.13) | |
Free Cash Flow |
(2.69) | (3.34) | (2.99) | (3.10) | |
| Other line items | |||||
Cash ROIC |
(21.76%) | (25.64%) | (20.33%) | (20.12%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
— | — | — | 0.00 | |
Days of Inventory on Hand |
— | — | — | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 9.51% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 424.32% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 239.17% | |
Interest Coverage |
(41.95) | (33.13) | (17.19) | (9.43) | |
Operating CF/Net income |
0.38 | 0.39 | 0.38 | 0.53 | |
Depreciation/Fixed assets |
0.04 | 0.04 | 0.04 | 0.01 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.06 | |
Operating CF per Share |
(0.10) | (0.13) | (0.15) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates · fundamentals updated 28 Sep 2026